{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:06:28Z","timestamp":1781888788110,"version":"3.54.5"},"reference-count":75,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmol Eye Dis"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To summarize evidence-based indications of topical 0.1% tacrolimus in treating ophthalmological diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature review was conducted using PubMed, Embase, and Wanfang databases. Two independent reviewers screened studies according to predefined criteria: original human research (case reports\/series, prospective\/retrospective studies, RCTs) on ophthalmic applications of 0.1% tacrolimus were included, while reviews, conference abstracts, non-ophthalmic studies, alternative formulations\/routes, and preclinical studies were excluded. Two reviewers independently extracted data using a piloted form, resolving discrepancies through thorough discussion. Extracted variables included study details (author, year, design, location), population characteristics (patients\/eyes), and intervention protocols. Data were synthesized thematically by ocular disease category, with comparative analysis of study designs, treatment regimens, and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>0.1% topical tacrolimus significantly improves the signs and symptoms of a wide spectrum of inflammatory eye conditions of the anterior segment, namely allergic conjunctivitis, viral conjunctivitis, immune checkpoint inhibitor-related conjunctivitis, ocular cicatricial pemphigoid, nodular episcleritis, graft rejection, graft-versus-host diseases, dry eye disease, autoimmune keratitis, blepharitis, and periorbital dermatitis. In addition to monotherapy, 0.1% tacrolimus can be used as an adjunct alongside other medications such as topical steroids and topical cyclosporine. The medication is generally well-tolerated with minimal side effects, with the most common complaint being local stinging, which dampens over time. Its reassuring safety profile in the ocular application is evidenced by its minimal systemic absorption post-administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>0.1% tacrolimus is effective and safe for a wide spectrum of eye diseases involving the anterior segment and adnexa. Not only does 0.1% topical tacrolimus spare patients from the side effects of chronic topical corticosteroid use but it also emerges as an option for patients inadequately managed by other immunosuppressants, highlighting the growing significance of 0.1% tacrolimus in ophthalmic practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25158414251405461","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:04:26Z","timestamp":1770379466000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The evidence-based indications of 0.1% topical tacrolimus in ophthalmology: a scoping review"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4779-5824","authenticated-orcid":false,"given":"Patricia Dorothy","family":"Lam","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3184-9280","authenticated-orcid":false,"given":"Jacqueline W. T.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China"},{"name":"Hong Kong Eye Hospital, Kowloon, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-8919","authenticated-orcid":false,"given":"Rachel W. Y.","family":"Tsui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China"},{"name":"Hong Kong Eye Hospital, Kowloon, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China"},{"name":"Hong Kong Eye Hospital, Kowloon, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5029-8621","authenticated-orcid":false,"given":"Vanissa W. S.","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China"},{"name":"Hong Kong Eye Hospital, Kowloon, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2504-9532","authenticated-orcid":false,"given":"Julia Y. Y.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China"},{"name":"4\/F, Hong Kong Eye Hospital, Kowloon, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.1249"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103945"},{"key":"e_1_3_4_4_2","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.","journal-title":"BMJ"},{"key":"e_1_3_4_5_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.7869\/djo.84"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.10.065"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.798998"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0087"},{"key":"e_1_3_4_10_2","article-title":"Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis","volume":"15","author":"Saha BC","year":"2023","unstructured":"Saha BC, Kumari R, Ambasta A. Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis. Ther Adv Ophthalmol 2023; 15: 25158414231173532.","journal-title":"Ther Adv Ophthalmol"},{"key":"e_1_3_4_11_2","first-page":"932","article-title":"Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis","volume":"17","author":"Wakamatsu TH","year":"2011","unstructured":"Wakamatsu TH, Tanaka M, Satake Y, et al. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis. Mol Vis 2011; 17: 932\u2013938.","journal-title":"Mol Vis"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000478704"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-9233.164616"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.11.002"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.650083"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003404"},{"issue":"3","key":"e_1_3_4_17_2","first-page":"177","article-title":"A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children","volume":"30","author":"Labcharoenwongs P","year":"2012","unstructured":"Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012; 30(3): 177\u2013184.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12360"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.11-OA-0349"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304453"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.10.006"},{"issue":"6","key":"e_1_3_4_22_2","article-title":"Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases","volume":"10","author":"Barot RK","year":"2016","unstructured":"Barot RK, Shitole SC, Bhagat N, et al. Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases. J Clin Diagn Res 2016; 10(6): NC05\u2013NC09.","journal-title":"J Clin Diagn Res"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040895"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03774-2"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2025.102268"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0151-9638(06)70869-9"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000341"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000696"},{"issue":"10","key":"e_1_3_4_29_2","article-title":"Treatment of steroid-resistant nodular episcleritis with tacrolimus: a case report","volume":"15","author":"Alghamdi AH","year":"2023","unstructured":"Alghamdi AHSr. Treatment of steroid-resistant nodular episcleritis with tacrolimus: a case report. Cureus 2023; 15(10): e47057.","journal-title":"Cureus"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002938"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0108"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03506-6"},{"issue":"4","key":"e_1_3_4_33_2","first-page":"3260","article-title":"Tacrolimus dye drop treatment for the management of early post-operative intraocular inflammation after therapeutic keratoplasty for severe infectious keratitis","volume":"20","author":"Zang Y","year":"2020","unstructured":"Zang Y, Li S, Ruan F, et al. Tacrolimus dye drop treatment for the management of early post-operative intraocular inflammation after therapeutic keratoplasty for severe infectious keratitis. Exp Ther Med 2020; 20(4): 3260\u20133268.","journal-title":"Exp Ther Med"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2019.1600197"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0717-3"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02318-w"},{"issue":"6","key":"e_1_3_4_37_2","first-page":"419","article-title":"[The effectiveness and safety of topical 0.1% tacrolimus after high-risk penetrating keratoplasty]","volume":"55","author":"Li X","year":"2019","unstructured":"Li X, Zhang YN, Yin MY, et al. [The effectiveness and safety of topical 0.1% tacrolimus after high-risk penetrating keratoplasty]. Zhonghua Yan Ke Za Zhi 2019; 55(6): 419\u2013427.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"issue":"3","key":"e_1_3_4_38_2","first-page":"251","article-title":"Effect of tacrolimus eye drops on immune rejection after high-risk corneal transplantation","volume":"23","author":"Liao XM","year":"2020","unstructured":"Liao XM, Feng X, Shangguan GH. Effect of tacrolimus eye drops on immune rejection after high-risk corneal transplantation. China Pharmacist 2020; 23(3): 251.","journal-title":"China Pharmacist"},{"issue":"3","key":"e_1_3_4_39_2","article-title":"The immunosuppressive activity of tacrolimus eye drops in high-risk corneal transplantation","volume":"25","author":"Zhang LT","year":"2017","unstructured":"Zhang LT, Li SX, Zhang N, et al. The immunosuppressive activity of tacrolimus eye drops in high-risk corneal transplantation. J Clin Ophthalmol 2017; 25(3): 193\u2013196.","journal-title":"J Clin Ophthalmol"},{"issue":"4","key":"e_1_3_4_40_2","first-page":"289","article-title":"Efficacy of FK506 in the treatment of dry eye patients with chronic graft-versus-host disease","volume":"25","author":"Gu ZY","year":"2017","unstructured":"Gu ZY, Liao RF. Efficacy of FK506 in the treatment of dry eye patients with chronic graft-versus-host disease. J Clin Ophtahlmol 2017; 25(4): 289\u2013292.","journal-title":"J Clin Ophtahlmol"},{"issue":"10","key":"e_1_3_4_41_2","first-page":"805","article-title":"[Efficacy evaluation of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in the treatment of severe dry eye associated with chronic graft-versus-host disease]","volume":"59","author":"Liu SW","year":"2023","unstructured":"Liu SW, Zhao YH, Ma J, et al. [Efficacy evaluation of 0.05% cyclosporine A and 0.1% tacrolimus eye drops in the treatment of severe dry eye associated with chronic graft-versus-host disease]. Zhonghua Yan Ke Za Zhi 2023; 59(10): 805\u2013813.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"issue":"4","key":"e_1_3_4_42_2","article-title":"Application of tacrolimus in the treatment of graft-versus-host disease dry eye after peripheral blood stem cell transplantation","volume":"37","author":"Zheng HY.","year":"2024","unstructured":"Zheng HY. Application of tacrolimus in the treatment of graft-versus-host disease dry eye after peripheral blood stem cell transplantation . Heilongjiang Med J 2024; 37(4): 796\u2013800.","journal-title":"Heilongjiang Med J"},{"issue":"1","key":"e_1_3_4_43_2","article-title":"Effects of autologous serum combined with 0.1%tacrolimus eye drops in the treatment of dry eye caused by chronic graft-versus-host disease","volume":"23","author":"Li W","year":"2021","unstructured":"Li W, Zhang B, He W. Effects of autologous serum combined with 0.1%tacrolimus eye drops in the treatment of dry eye caused by chronic graft-versus-host disease. J Shenyang Med Coll 2021; 23(1): 15\u201321.","journal-title":"J Shenyang Med Coll"},{"issue":"9","key":"e_1_3_4_44_2","first-page":"1694","article-title":"Efficacy of single dose dermatological 0.1% tacrolimus Ointment in the treatment of vernal keratoconjunctivitis","volume":"72","author":"Sharjeel M","year":"2022","unstructured":"Sharjeel M, Iqbal U, Jabran A, et al. Efficacy of single dose dermatological 0.1% tacrolimus Ointment in the treatment of vernal keratoconjunctivitis. J Pak Med Assoc 2022; 72(9): 1694\u20131698.","journal-title":"J Pak Med Assoc"},{"issue":"9","key":"e_1_3_4_45_2","article-title":"Comparative study on clinical efficacy and safety of different doses of tacrolimus eye drops in the treatment of patients with keratoconjunctivitis","volume":"24","author":"Wang QZ","year":"2024","unstructured":"Wang QZ, Liu Y, Li JP. Comparative study on clinical efficacy and safety of different doses of tacrolimus eye drops in the treatment of patients with keratoconjunctivitis. Evaluation and analysis of drug-use in hospitals of China. 2024; 24(9): 1063\u20131066.","journal-title":"Evaluation and analysis of drug-use in hospitals of China"},{"issue":"4","key":"e_1_3_4_46_2","first-page":"378","article-title":"[Follow-up study on patients with vernal keratoconjunctivitis undergoing topical 0.1% tacrolimus treatment]","volume":"118","author":"Harada N","year":"2014","unstructured":"Harada N, Inada N, Ishimori A, et al. [Follow-up study on patients with vernal keratoconjunctivitis undergoing topical 0.1% tacrolimus treatment]. Nippon Ganka Gakkai Zasshi 2014; 118(4): 378\u2013384.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"9","key":"e_1_3_4_47_2","first-page":"3499","article-title":"The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of scleritis","volume":"60","author":"Yazu H","year":"2019","unstructured":"Yazu H, Miyazaki D, Fujishima H. The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of scleritis. Investig Ophthalmol Visual Sci 2019; 60(9): 3499.","journal-title":"Investig Ophthalmol Visual Sci"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2018.07.018"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04287-1"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002751"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00513-w"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002692"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31823f8c9b"},{"issue":"23","key":"e_1_3_4_54_2","article-title":"0.1% tacrolimus eye drops in the treatment of refractory immune associated keratopathy","volume":"34","author":"Liu HY.","year":"2018","unstructured":"Liu HY. 0.1% tacrolimus eye drops in the treatment of refractory immune associated keratopathy. Chin Commun Doctors 2018; 34(23): 26\u201328.","journal-title":"Chin Commun Doctors"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.83.31"},{"issue":"3","key":"e_1_3_4_56_2","first-page":"197","article-title":"Efficacy of 0.1% tacrolimus eye drops in the treatment of refractory immunologic keratitis","volume":"25","author":"Zhang N","year":"2017","unstructured":"Zhang N, Li SX, Zhang LT, et al. Efficacy of 0.1% tacrolimus eye drops in the treatment of refractory immunologic keratitis. J Clin Ophthalmol 2017; 25(3): 197\u2013201.","journal-title":"J Clin Ophthalmol"},{"issue":"4","key":"e_1_3_4_57_2","first-page":"207","article-title":"Effect of topical FK506 used alone or combined with keratoplasty on patients with recurrent Mooren\u2019s corneal ulcer","volume":"22","author":"Xie H","year":"2006","unstructured":"Xie H, Chen J, Lin Y, et al. Effect of topical FK506 used alone or combined with keratoplasty on patients with recurrent Mooren\u2019s corneal ulcer. Yan Ke Xue Bao 2006; 22(4): 207\u2013213.","journal-title":"Yan Ke Xue Bao"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad339"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.2340\/0001555571452454"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-18665"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00323.x"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e318203d81f"},{"issue":"4","key":"e_1_3_4_63_2","first-page":"267","article-title":"Tacrolimus ointment in the treatment of eyelid dermatitis","volume":"73","author":"Freeman AK","year":"2004","unstructured":"Freeman AK, Serle J, VanVeldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 2004; 73(4): 267\u2013271.","journal-title":"Cutis"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03056.x"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702367"},{"issue":"1","key":"e_1_3_4_66_2","article-title":"Tacrolimus ointment in periorbital atopic dermatitis","volume":"16","author":"Alzahrani M","year":"2024","unstructured":"Alzahrani M, Kamal YF, Akram MA. Tacrolimus ointment in periorbital atopic dermatitis. Cureus 2024; 16(1): e53055.","journal-title":"Cureus"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_2944_22"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(01)00059-5"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.11.9.16"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328364db84"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2007.0083"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200403000-00013"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12292"},{"issue":"1","key":"e_1_3_4_74_2","first-page":"13","article-title":"[Effect of FK506 eye-drop combined with keratoplasty on recurrent Mooren\u2019s ulcer]","volume":"38","author":"Xie H","year":"2002","unstructured":"Xie H, Chen J, Lin Y, et al. [Effect of FK506 eye-drop combined with keratoplasty on recurrent Mooren\u2019s ulcer]. Zhonghua Yan Ke Za Zhi 2002; 38(1): 13\u201315.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002674"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000001180"}],"container-title":["Therapeutic Advances in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25158414251405461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25158414251405461","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25158414251405461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:41:00Z","timestamp":1777596060000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25158414251405461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":75,"alternative-id":["10.1177\/25158414251405461"],"URL":"https:\/\/doi.org\/10.1177\/25158414251405461","relation":{},"ISSN":["2515-8414","2515-8414"],"issn-type":[{"value":"2515-8414","type":"print"},{"value":"2515-8414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"25158414251405461"}}